EVGN - Conference and earnings call announcements

Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, SpainREHOVOT, Israel, Oct. 26, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in two upcoming industry conferences in Europe: BIO-Europe, to be held November 9-11, 2026, in Cologne, Germany, and Drug Discovery Chemistry Europe, to be held November 10-12, 2026, in Barcelona, Spain. At BIO-Europe

The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partnersREHOVOT, Israel, Oct. 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for pharmaceutical and agricultural applications, today announced its participation in the AI Drug Discovery Roadshow, taking place November 2-5, 2026, across the U.S. East Coast. Organized by the Israel Export Institute and TradeIL, the roadshow aims to strengthen

Conference will be held in Munich, Germany - May 19-21, 2026REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in the 24th Schrödinger European User Group Meeting, taking place May 19–21, 2026, in Munich, Germany. Bringing together industry and academic experts to share advances and real-world applications in computational drug discovery, Evogene has been chosen to present its recent progress in generative design of novel compounds. Dr. Roberto Olender, Evogene's He

REHOVOT, Israel, Aug. 28, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference, 2025, taking place in New York, from September 8-10, 2025. Mr. Haviv's in-person presentation will highlight Evogene's new strategic focus on maximizing the value of ChemPass AI, the company's proprietary generative AI tech-engine, for the discovery and optimization of small molecules in both the pharmaceutical and agriculture industries. The presentation is scheduled for Wednesday, September 10, 2025, at 1:00 P

Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel, April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in refractory patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), who previously progressed on immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The confe

REHOVOT, Israel, April 11, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ:EVGN, TASE: EVGN))), today announced that it will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting. The conference is being held in Washington, D.C., May 18-21, 2024. The pre-clinical work was led by Prof. Yehuda Ringel, Biomica's Co-Founder and CSO, in collaboration with the lab of Prof. Kara Gross Margolis, at the NYU Grossman School of Medicine. In the studies, Biomica tested two candidate therapeuti

The grant under the EU Horizon Program was approved following the successful proof of concept from the previous program launched in 2016 REHOVOT, Israel, May 9, 2023 /PRNewswire/ -- The Ag-Seed Division of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) ("Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments has announced that it has been granted a prestigious EU Horizon grant of €1.2 million, to support the creation of oil-seed crops that have high carbon-dioxide assimilation and enhanced drought tolerance. The project, Crop4Clima, has an overall budget of €2.5 million and is expected to be execut

REHOVOT, Israel, March 15, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced that its VP R&D, Dr. Shiri Meshner, will be presenting at the Pharmabiotics 2023 Conference, 'The Future of Microbiome-based Medicines', taking place in Lyon, France from March 21-22, 2023. Dr. Meshner will be presenting on March 21, at 3:40pm CET, in a presentation entitled, 'Biomica's BMC128 - a Rationally Designed LBP Consortium's Journey to the Clinic.' Biomica's proprietary BMC128 is a rationally designed consortia of 4 live bacterial strains which demonstr

REHOVOT, Israel, March 1, 2023 /PRNewswire/ -- Biomica, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced it will be presenting at the 2023 ECCO Annual Meeting taking place in Copenhagen, Denmark from March 1 to 4, 2023.   The European Crohn's and Colitis Organization (ECCO) annual congress is an international leading meeting focusing on state-of-the-art clinical approaches and cutting-edge research and advances in Inflammatory Bowel Diseases (IBD). Professor Yehuda Ringel, Biomica's Chief Scientific Officer (CSO), will be presenting recent data from Biomica's IBD R&D pip

REHOVOT, Israel, March 1, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will attend and meeting with investors at the 35th Annual ROTH Conference being held in Dana Point, California on March 13-14, 2023. The conference will feature one-on-one and small group meetings, industry panels, presentations and fireside chats. The Roth conference typically draws thousands of attendees, including institutional investors, analysts, family offices and high net-worth investors. Evogene's Executive VP, Business Development,

REHOVOT, Israel, Jan. 24, 2023 /PRNewswire/ --  Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.    The 7th Microbiome Movement – Drug Development Summit Europe aims to unite Europe's leading drug developers and microbiome experts to share their latest discoveries on microbiome functionality, translation, clinical development, biomarker discovery and manufacturing scale-up. In attendan

REHOVOT, Israel , Nov. 14, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced it will be participating in an Industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit taking place between November 16-17, 2022, in Boston, MA. The conference is dedicated to showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. In attendance will be Dr. Elran Haber, CEO of Biomica. Dr. Haber will be part of an indu

REHOVOT, Israel, Oct. 6, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN, TASE: EVGN))) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Ofer Haviv, Evogene's President and CEO, will attend and present at LD Micro Main Event, an investor conference taking place from Tuesday, October 25 to Wednesday, October 26, 2022, in Los Angeles. The event is a leading small cap investor conference, showcasing over 200 small- and micro-cap companies. Mr. Haviv is scheduled to present on Tuesday, October 25 at 10am PT in Track 4 and will be available for 1-1 meet

REHOVOT, Israel, Sept. 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Ofer Haviv, Evogene's President and CEO, will attend virtually and present at the H.C. Wainwright 24th Annual Global Investment Hybrid Conference, 2022, taking place from September 12-14, 2022, in New York and also in a virtual format.   Mr. Haviv's presentation will focus on Evogene's disruptive technologies, its AI engines for biologic product discovery and development, and the ecosystem of product-focused subsi

REHOVOT, Israel, July 5, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam, Netherlands.   The Annual Microbiome Connect Europe is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers. In attendance will be Dr. Shiri Meshner, VP R&D at Biomica, who will be pr

Dr. Elran Haber to participate in the Industry Leaders opening panel at this premier Microbiome conference REHOVOT, Israel, June 15, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced it will be presenting as part of a panel at the opening session of the 7th Microbiome Movement Drug Development Summit taking place between June 21-24, 2022 in Boston, MA.     The event is known in the field as the most comprehensive forum for microbiome drug developers and an opportunity for the industry to take a collaborative approach, discuss next-generation

REHOVOT, Israel, May 23, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced it will be presenting at the 2022 ASCO Annual Meeting, a conference taking place in Chicago, IL from June 3 to 7, 2022. The ASCO (American Society of Clinical Oncology) Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific g

REHOVOT, Israel, May 16, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced it will be presenting at the Digestive Disease Week (DDW 2022) Conference taking place May 21-24, 2022, in San Diego, California.     DDW is the world's premier meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.  Professor Yehuda Ringel, CSO of Biomica, will be presenting on May 22, 2022 from 4:00 PM to 5:30 PM PDT. The presentation is entitled, "Anti-Inflammatory effect of a rational

  REHOVOT, Israel, March 14, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN, TASE: EVGN))), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the Jefferies Virtual Synthetic Biology Week which is taking place between March 21-25, 2022. Evogene's Chief Product Officer, Dr. Nir Arbel, will participate in a fireside chat at 10am ET on Wednesday, March 23, 2022. Dr. Arbel, will also be available for one-on-one virtual meetings with investors on Thursday, March 24, 2022. Investors that wish to meet with Dr. Arbel, are welcome to coordinate the meeting via their J

REHOVOT, Israel, March 3, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will present at the 34th Annual ROTH Conference being held both virtually and in-person in Dana Point, California on March 13-15, 2022. The conference will feature on-demand online and live presentations from companies across a variety of sectors, one-on-one and small group meetings, industry panels, and fireside chats. Past conferences have drawn thousands of attendees, including institutional investors, analysts, family offices and high n

REHOVOT, Israel, Feb. 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments announced today that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25th at 9:00 Eastern. The conference will span three days, starting on February 23rd until February 25th from 8:30AM until 5PM EST.    Evogene's presentation will be available by request to Aegis from February 23 to 25, 2022. The slide deck will also be made available on Evogene's website at https://www.evogene.com/investor-relations/presentations-and-web

REHOVOT, Israel, Jan. 19, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), announced today it is participating in Edison Group's Open House Event, scheduled to take place virtually this month.  For more information on the event and details on how to register, please see below. Edison Group:Global Healthcare Open House Conference 2022Date: January 25-27th, 2022Event information  Presentation information: The company presentation will be available on demand on http://www.edisongroup.com beginning at 7am ET on Thursday, January 27th.  A replay of the presentation will also be available on Evogene's investor relations page. 1x1 Meeting Registration: To register for a 1x1 meetings w

REHOVOT, Israel, Sept. 14, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational predictive biology company aiming to revolutionize life-science product development acros\s several market segments, announced today that Mr. Ofer Haviv, Evogene's President and CEO, will be interviewed in a "Fireside Chat" at the Cantor Virtual Global Healthcare Conference taking place on September 27-30, 2021. Mr. Haviv's  interview will focus on Evogene's disruptive technologies; its tailor-made engines for product discovery and development and its fields of activity through its main subsidiaries and will take place on Tuesday September 28, 2021, at 10:40 am, EST and will be av

REHOVOT, Israel, Sept. 1, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, 2021, taking place from September 9-15, 2021. Mr. Haviv's presentation will focus on Evogene's disruptive technologies, its tailor-made engines for product discovery and development and its fields of activity through its main subsidiaries, and will take place on Thursday September 9, 2021, at 07:30 am, EST.     Investors attending the confe

REHOVOT, Israel, April 19, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.      Dr. Haber will be available for one-on-one meetings during the summit. A Pre-Recording of the Presentation will be made available on Thursday, April 22, 2021. About Biomica: Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated

REHOVOT, Israel, April 7, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company today announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars. The meetings will feature key-note presentations from Evogene's CEO, Ofer Haviv, and the CEOs of Evogene group subsidiaries Biomica, Canonic, AgPlenus, and Lavie Bio, followed by a question and answer session. The Hebrew language event will be held on Monday, April 19, 2021 at 4pm IST or 9am ET. To register for this event, please visit the link:https://zoom.us/webinar/register/WN_MpdKOdKeTvqyR6LDbpJlCQ  The English language event will be held on W

REHOVOT, Israel, Jan. 21, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn's & Colitis Congress®  to be held from today January 21-24, 2021. Prof. Yehuda Ringel, CSO of Biomica, will present "BMC322 - A rationally-designed live bacterial consortium based on microbiome functional genomic analysis for treatment of IBD" on Saturday 23rd January, 2021 at 2PM (EST). The Crohn's & Colitis Congress is jointly organized by the American Crohn's & Colitis Foundation (CCFA) and the Ameri

REHOVOT, Israel, Jan. 20, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference.  The conference is being held on January 28-29, 2021, virtually.Dr. Elran Haber, Biomica's Chief Executive Officer, is scheduled to speak on the European Microbiome Leaders Panel during the morning opening plenary session on January 28 at 9:00 am CET. Biomica Logo Evogene Logo The panel discussion will address